Literature DB >> 1383319

Role of hapten-anchoring peptides in defining hapten-epitopes for MHC-restricted cytotoxic T cells. Cross-reactive TNP-determinants on different peptides.

S Martin1, B Ortmann, U Pflugfelder, U Birsner, H U Weltzien.   

Abstract

Synthetic hapten-peptide conjugates selectively modify cell-bound MHC class I molecules in a haplotype-specific way. We investigated the contribution of the carrier peptides to the structural specificity of T cell-antigenic TNP epitopes, using different H-2Kb-binding TNP-peptides and a collection of TNP/Kb-specific CTL clones. Adjustment of peptide sequences to the proposed Kb-specific "motif" (octamers with F or Y and L in positions 5 and 8, respectively) enhanced Kb-binding and antigenicity by many orders of magnitude. Moreover, several clones reacted to peptides, containing the "motif" and TNP-lysine in position 4 but were otherwise unrelated by sequence. TNP in other positions was not recognized by these cells, but other CTL reacted to TNP in position 7. This points to the positioning of hapten determinants within the MHC binding groove as a major role of the anchoring peptide. However, determination of the limiting amounts of TNP peptides that elicit antigenicity or inhibit other Kb-restricted CTL reactions revealed that TCR also recognize variations in the sequences of carrier peptides. This contribution is low for TNP in position 4 but high in position 7, indicating lysine in position 4 as a particularly dominant and cross-reactive hapten-anchoring site in Kb-associated peptides. This implies that cell modification with lysine-reactive TNP reagents results in immunodominant, highly repetitive TNP epitopes, which may explain the strong antigenicity and the allergenic properties of TNP, as well as the restricted TCR repertoire directed against this hapten. Our data further recommend hapten peptides for general studies of TCR-Ag interactions because in contrast to pure protein Ag, hapten epitopes tolerate substantial structural variations in the MHC-anchoring peptide, and can be located by hapten-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383319

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays.

Authors:  Stefan F Martin; Philipp R Esser; Sonja Schmucker; Lisa Dietz; Dean J Naisbitt; B Kevin Park; Marc Vocanson; Jean-Francois Nicolas; Monika Keller; Werner J Pichler; Matthias Peiser; Andreas Luch; Reinhard Wanner; Enrico Maggi; Andrea Cavani; Thomas Rustemeyer; Anne Richter; Hermann-Josef Thierse; Federica Sallusto
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

2.  Clonal anergy induced in a CD8+ hapten-specific cytotoxic T-cell clone by an altered hapten-peptide ligand.

Authors:  T Preckel; S Hellwig; U Pflugfelder; M B Lappin; H U Weltzien
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

3.  Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids.

Authors:  Varun Gauba; Jan Grünewald; Vanessa Gorney; Lisa M Deaton; Mingchao Kang; Badry Bursulaya; Weijia Ou; Richard A Lerner; Christian Schmedt; Bernhard H Geierstanger; Peter G Schultz; Teresa Ramirez-Montagut
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

4.  Dominant V beta 8 gene usage in response to TNP: failure to use other V beta chains following removal of V beta 8+ T cells by monoclonal antibody in vivo.

Authors:  F Dieli; G L Asherson; G Sireci; G Tantillo; C del Carpio; A Salerno
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

5.  Induction of tolerance by administration of hapten-immunoglobulin conjugates is associated with decreased IL-2 and IL-4 production.

Authors:  V Dumas; W Ptak; M Demarchez; J H Saurat; Y Borel; C Hauser
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  Processing of urushiol (poison ivy) hapten by both endogenous and exogenous pathways for presentation to T cells in vitro.

Authors:  R S Kalish; J A Wood; A LaPorte
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 7.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

8.  Altered hapten ligands antagonize trinitrophenyl-specific cytotoxic T cells and block internalization of hapten-specific receptors.

Authors:  T Preckel; R Grimm; S Martin; H U Weltzien
Journal:  J Exp Med       Date:  1997-05-19       Impact factor: 14.307

Review 9.  Drug and Chemical Allergy: A Role for a Specific Naive T-Cell Repertoire?

Authors:  Rami Bechara; Alexia Feray; Marc Pallardy
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

10.  Relationship between Poor Immunogenicity of HLA-A2-Restricted Peptide Epitopes and Paucity of Naïve CD8(+) T-Cell Precursors in HLA-A2-Transgenic Mice.

Authors:  Yoon Seok Choi; Dong Ho Lee; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2014-08-22       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.